J. M. Kremer, G.S. Alarcon, R.W Lightfoot Jr., R.F. Wilkins, D.E. Furst, and H. J. Williams et. al. “Methotrexate For Rheumatoid Arthritis. Suggested Guidelines For Monitoring Liver Toxicity. American College of Rheumatology,” Arthritis and Rheumatism Vol. 37, No. 3, 1994, pp. 316-328.
 J.M. Kremer, D.E. Furst, M.E. Weinblatt and S.D. Blotner SD. “Significant Changes In Serum AST Across Hepatic Histological Biopsy Grades: Prospective Analysis Of 3 Cohorts Receiving Methotrexate Therapy For Rheumatoid Arthritis,” Journal of Rheumatology Vol. 23, No. 3, 1996, pp. 459-461.
 P. D. Kent, H.S. Luthra and C Michet C, Jr. “Risk Factors For Methotrexate-Induced Abnormal Laboratory Monitoring Results In Patients With Rheumatoid Arthritis,” Journal of Rheumatology Vol. 31, No. 9: 2004, pp. 1727-1731.
 Y Yazici, D. Erkan, M.J. Harrison, N.P. Nikolov and S.A. Paget SA. “Methotrexate Use In Rheumatoid Arthritis Is Associated With Few Clinically Significant Liver Function Test Abnormalities,” Clinical and Experimental Rheumatology Vol. 23, No. 4, 2005, pp. 517-520.
 J. M. Kremer, R.G Lee and K.G. Tolman. “Liver Histology In Rheumatoid Arthritis Patients Receiving Long-Term Methotrexate Therapy. A Prospective Study With Baseline And Sequential Biopsy Samples,” Arthritis and Rheumatism Vol. 32, No. 2, 1989, pp. 121-127.
 C.A. Phillips, P.J. Cera, T.F. Mangan and E.D. Newman. “Clinical Liver Disease In Patients With Rheumatoid Arthritis Taking Methotrexate,” Journal of Rheumatology Vol. 19, No. 2, 1992, pp. 229-233.
 P.D. Hall, M.J. Ahern, L.R. Jarvis, P. Stoll, M.A. Jenner MA and H Harley. “Two Methods Of Assessment Of Methotrexate Hepatotoxicity In Patients With Rheumatoid Arthritis,” Annals of the Rheumatic Diseases Vol. 50, No. 7, 1991, pp. 471-476.
 R.F. Willkens, P.A. Leonard PA, D.O. Clegg, K G Tolman, J R Ward, C R Marks, M L Greene, G J Roth, C G Jackson, and G W Cannon et. al. “Liver Histology In Patients Receiving Low Dose Pulse Methotrexate For The Treatment Of Rheumatoid Arthritis,” Annals of the Rheumatic Diseases, Vol. 49, No. 8, 1990, pp. 591-593.
 Y. Yazici, T. Sokka, H. Kautiainen, C. Swearingen, I. Kulman and T. Pincus. “Long Term Safety Of Methotrexate In Routine Clinical Care: Discontinuation Is Unusual And Rarely The Result Of Laboratory Abnormalities,” Annals of the Rheumatic Diseases Vol. 64, No. 2, 2005, pp. 207-211.
 P. Asbach, D. Klatt, U. Hamhaber, J. Braun, R. Somasundaram, B. Hamm and I. Sack. “Assessment Of Liver Viscoelasticity Using Multifrequency MR Elastography,” Magnetic Resonance Medicine Vol. 60, No. 2, 2008, pp. 373-379.
 L Huwart, C. Sempoux, E. Vicaut, N. Salameh, L. Annet, E. Danse, F. Peeters, L.C. ter Beek, J. Rahier, R. Sinkus, Y. Horsmans and BE Van Beers. “Magnetic resonance elastography for the noninvasive staging of liver fibrosis,” Gastroenterology Vol. 135, No. 1, 2008, pp. 32-40.
 M. Yin, J.A. Talwalkar, K.J. Glaser, A. Manduca, R. C. Grimm, P. J. Rossman, J. L. Fidler, and R. L. Ehman. “Assessment Of Hepatic Fibrosis With Magnetic Resonance Elastography,” Clinics in Gastroenterology and Hepatology Vol. 5, No. 10, 2007, pp. 1207-1213 e2.
 S.H. Park, J.Y. Choe and S.K. Kim. “Assessment Of Liver Fibrosis By Transient Elastography In Rheumatoid Arthritis Patients Treated With Methotrexate,” Joint Bone Spine Vol. 77, No. 6, 2010, pp. 588-592.
 A.M. Walker, D. Funch, N.A. Dreyer, K.G. Tolman, J.M. Kremer, G.S. Alarcon, R.G. Lee and M.E. Weinblatt. “Determinants Of Serious Liver Disease Among Patients Receiving Low-Dose Methotrexate For Rheumatoid Arthritis,” Arthritis and Rheumatism, Vol. 36, No. 3, 1993, pp. 329-335.
 W.J. Shergy, R.P. Polisson, D.S. Caldwell, J.R. Rice, D.S. Pisetsky and N.B. Allen. “Methotrexate-Associated Hepatotoxicity: Retrospective Analysis Of 210 Patients With Rheumatoid Arthritis,” American Journal of Medicine, Vol. 85, No. 6, 1988, pp. 771-774.
 H.H. Roenigk, Jr., R. Auerbach, H. Maibach, G. Weinstein and M. Lebwohl. “Methotrexate In Psoriasis: Consensus Conference,” Journal of the American Academy of Dermatology, Vol. 38, No. 3, 1998, pp. 478-485.